Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial
RCT 190 hospitalized severe condition patients in Mexico, showing no significant difference between convalescent plasma and human immunoglobulin treatment.
risk of death, 6.5% higher, RR 1.07, p = 0.76, treatment 60 of 130 (46.2%), control 26 of 60 (43.3%), day 28, intention-to-treat.
|
risk of death, 1.0% higher, RR 1.01, p = 1.00, treatment 70 of 130 (53.8%), control 32 of 60 (53.3%), followup, day 28, intention-to-treat.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Gonzalez et al., 31 Mar 2021, retrospective, Mexico, preprint, 17 authors, study period 5 May, 2020 - 17 October, 2020, this trial compares with another treatment - results may be better when compared to placebo, trial
NCT04381858 (history).
Contact:
dr.jmag@gmail.com, mariogzg@hotmail.com.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.28.21254507; this version posted March 31, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill
COVID-19 patients. A controlled clinical trial.
1
1
Jose Lenin Beltran Gonzalez MD , Mario González Gámez MD , Emmanuel Antonio Mendoza
1
1
1
Enciso MD , Ramiro Josue Esparza Maldonado MD , Daniel Hernández Palacios MD , Samuel
1
1
1
Dueñas Campos MD , Itzel Ovalle Robles MD , Mariana Jocelyn Macías Guzmán MD , Andrea Lucia
1
1
1
García Díaz MD , César Mauricio Gutiérrez Peña MD , Ana Lilian Reza-Escalera MD , Maria Teresa
1
2
3
Tiscareño Gutierrez MD , Elva Galvan-Guerra QFB , Maria del Rocio Dorantes Morales MD , Lucila
4
4
Martínez Medina MD, MSc. , Victor Antonio Monroy Colin MD , Arreola Guerra Jose Manuel MD
1
MSc, PhD .
1.
Internal Medicine Department Centenario Hospital Miguel Hidalgo
2.
Laboratorio Clinico del Campestre
3.
Aguascalientes State Transfusion Center
4.
Pediatrics Department Centenario Hospital Miguel Hidalgo
Corresponding Authors:
José Manuel Arreola Guerra, MD, M. Sc., Ph.D
Head, Department of Investigation, Nephrologist, and Associate Professor of Internal Medicine.
Hospital Centenario Miguel Hidalgo
Av Gómez Morín y Av La Estación, La Alameda, Aguascalientes, Aguascalientes Mexico.
C.P. 20259
Tel.: 521 4499946720
dr.jmag@gmail.com
Mario Gonzalez Gamez MD
Department of Internal Medicine and Infectologist
Hospital Centenario Miguel Hidalgo
Av Gómez Morín y Av La Estación, La Alameda, Aguascalientes, Aguascalientes Mexico.
C.P. 20259
Tel.: 521 4499946720
mariogzg@hotmail.com
Summary
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2021.03.28.21254507; this version posted March 31, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Background
The proportion of critically ill COVID-19 patients has collapsed hospital care worldwide. The
need for alternative therapies for this group of patients is imperative. This study aims to compare
the safety and efficacy of convalescent plasma (CP) compared with human immunoglobulin (IVIg)
in patients requiring the administration of high oxygen levels or mechanical ventilation.
Methods
This is a controlled, randomized, open clinical trial of patients with pneumonia secondary to
SARS-CoV-2 infection, that fulfilled criteria for severe or critical disease. They were randomized in
a 1:2 ratio; group 1 was administered IVIg at a dose of 0.3 grams per kilogram of ideal weight, in
an 8- hour infusion every 24 hours, for 5 days. Group 2 was administered 200 ml of CP infused in 2
hours, for 2 days. The primary outcomes were duration of hospitalization and mortality at 28 days.
Results:
One hundred and ninety (190) patients were randomized; 130 to the CP group, and 60 to the
IVIg group. Their average age was 58 years (IQR 47 – 72), and most were male (n= 119, 62.6 %). On
inclusion, 85.2 % of patients (n=162) were on..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit